e-Drug3D

1987

PEMIGATINIB

INN
PEMIGATINIB

cas 1513857-77-6

CLASS

ANTINEOPLASTIC
FGFR1, 2 AND 3 KINASE INHIBITOR
TREATMENT OF METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2)

ROUTE (list)

ORAL

ATC code

L01EN02

PK parameters

Tmax 1.13 HOUR
VD 235 LITER
Cl 10.6 LITER / HOUR
PPB 90.6 PERCENT
t1/2 15.4 HOUR

Target

TARGET FGFR1
FGFR2
FGFR3

PDB
7WCL (CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN WITH PEMIGATINIB)

Download experimental 3D coordinates of 8ZF with added hydrogens

Fibroblast growth factor receptor 3 UNIPROT P22607 FGFR3

Fibroblast growth factor receptor 1 UNIPROT P11362 FGFR1

Download SDF file

2H-Pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-

Formula:
C24H27F2N5O4

Calculated chemical properties:

MW 487.51
NB_atoms 35
XLogP 3.66
PSA 83.27
NB_HD 1
NB_HA 9
fsp3 0.42
Lipinski(0=no;1=yes) 1

FDA
NDA 213736 (pdf not found) INN (PEMIGATINIB) PEMAZYRE (INCYTE CORP) APPROVAL= AP YEAR= 2020 NEWMOLECULARENTITY